Board of Directors
Board of Directors
Dr. Fred Eshelman, PHD
Chairman of the Board
Dr. Eshelman has been a member of our Board of Directors since December 2014. He has more than 35 years of strategic development, executive, operational and financial leadership experience in the pharmaceutical and healthcare industries. Dr. Eshelman was the founder of Pharmaceutical Product Development, Inc. (NASDAQ: PPDI, before going private in 2011) and founding chairman of Furiex Pharmaceuticals, Inc. (NASDAQ: FURX, acquired by Actavis plc (NYSE: ACT)) from October 2009 to July 2014. Since April 2017, Dr. Eshelman has been serving as the chief executive officer of Innocrin Pharmaceuticals, Inc. Since September 2015, he has been serving as the executive chairman of The Medicines Company, Inc. (NASDAQ: MDCO). In May 2014, Dr. Eshelman founded Eshelman Ventures, LLC, an investment company focused on healthcare companies. From July 2009 to December 2011, he served as executive chairman of Pharmaceutical Product Development. He also served as chief executive officer of Pharmaceutical Product Development from July 1990 to July 2009 and as vice chairman of its board of directors from July 1993 to July 2009. Dr. Eshelman currently serves on the board of directors of Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and G1 Therapeutics, Inc. (NASDAQ: GTHX). Dr. Eshelman received a B.S. in pharmacy from UNC Chapel Hill and a Pharm.D. from the University of Cincinnati, and he completed an OPM program at Harvard University. Dr. Eshelman also received an honorary Doctor of Science from UNC Chapel Hill.
Sean Ianchulev, MD MPH
CEO, CMO & Director
Dr. Ianchulev has been serving as our Chief Executive Officer and Chief Medical Officer and a member of our Board of Directors since March 2014. From 2009 to 2016, he was the chief medical officer and the head of technology and business development for Transcend Medical, Inc. (acquired by Novartis International AG/Alcon, Inc. (NYSE: NVS)). Prior to that, while at Genentech, Inc. (Nasdaq: DNA, before going private in 2009), Dr. Ianchulev headed the ophthalmology research group and directed the development and the FDA approval of Lucentis. Dr. Ianchulev received his B.S. from the University of Rochester. He received both his M.D. and an M.P.H. from Harvard University and completed his specialty training at the Doheny Eye Institute. Currently, Dr. Ianchulev serves as a professor in the New York Eye and Ear Infirmary of Mount Sinai.
Dr. Curt Labelle, MD MBA
Dr. LaBelle has been investing in and working with healthcare companies for over 16 years. He is the managing partner of the Global Health Investment Fund which invests in companies developing products for conditions that disproportionately affect the developing world. He has served as a Board member or observer for many successful companies, including KAI Pharmaceuticals (sold to Amgen), Sirion Therapeutics (sold to B&L and Alcon), Impulse Monitoring (sold to NuVasive), TransMolecular (sold to Morphotek), Estech (sold to Atricure), Coherex (sold to J&J), Exagen Diagnostics, SafeOp among others. Dr. Labelle obtained his MD from Columbia University’s College of Physicians and Surgeons, MBA from Columbia University Business School and Bachelors in Economics from Brigham Young University.
Kenneth B. Lee, Jr.
Mr. Lee has been a member of our Board of Directors since March 2018. Since January 2003, he has been a general partner of Hatteras Venture Partners, LLC, a venture capital fund focusing on life science companies since January 2003. Previously he was president of A.M. Pappas & Associates, LLC, following 29 years with Ernst & Young LLP, where he was most recently managing director of the firm’s health sciences corporate finance group. Mr. Lee serves on the boards of Aralez Pharmaceuticals, Inc. (NASDAQ: ARLZ) and BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX). Previously, Mr. Lee has served on the boards of several private companies and public companies, including Abgenix, Inc. (NASDAQ: ABGX, acquired by Amgen, Inc.), CV Therapeutics Inc. (NASDAQ: CVTX, acquired by Gilead Sciences, Inc.), Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH, acquired by Merck &Co., Inc.), Maxygen, Inc. (NASDAQ: MAXY, dissolved), OSI Pharmaceuticals, Inc. (NASDAQ: OSIP, acquired by Astellas Pharma Inc.). Mr. Lee received a B.A. from Lenoir-Rhyne College and an M.B.A. from the University of North Carolina at Chapel Hill.
Ernest Mario, PHD
Dr. Mario has been a member of our Board of Directors since December 2014. Since April 2014, Dr. Mario has served as chairman of Soleno Therapeutics, Inc. ((NASDAQ: SLNO) formerly Capnia, Inc.), a specialty pharmaceutical company in Palo Alto, CA. Dr. Mario joined Pappas Ventures as a member of their Scientific Advisory Board in September 2002 and has been a venture partner since December 2011. Between August 2007 and February 2014, Dr. Mario served as the chief executive officer and chairman of Soleno Therapeutics, and between February 2014 and April 2014, Dr. Mario served as executive chairman. From April 2003 to August 2007, he was chairman and chief executive officer of Reliant Pharmaceuticals, Inc., a privately held pharmaceutical company. Dr. Mario is currently a director of Soleno Therapeutics (since February 2013), Kindred Biosciences, Inc. (since February 2013) (NASDAQ: KIN), Chimerix, Inc. (since February 2013) (NASDAQ: CMRX), TONIX Pharmaceuticals Holding Corp. (since October 2011) (NASDAQ: TNXP) and Celgene Corporation (since August 2007) (NASDAQ: CELG). Dr. Mario is also chairman of Chimerix. Dr. Mario previously served as a director of Boston Scientific Corporation (October 2001– May 2016) (NYSE: BSX), VIVUS Inc. (April 2012– July 2013) (NASDAQ: VVVS), XenoPort, Inc. (June 2012– May 2015) (NASDAQ: XNPT, until its acquisition by Arbor Pharmaceuticals, LLC), and Maxygen Inc. (July 2001– August 2013) (NASDAQ: MAXY). Dr. Mario was the deputy chairman and chief executive officer of Glaxo Holdings plc from May 1989 to March 1993 and chairman and chief executive officer of ALZA Corporation from November 1997 to December 2001 and chief executive officer from August 1993 to November 1997. He serves as an advisor to The Ernest Mario School of Pharmacy at Rutgers University. In 2007, Dr. Mario was awarded the Remington Medal by the American Pharmacists’ Association, pharmacy’s highest honor. Dr. Mario received a Ph.D. and an M.S. in physical sciences from the University of Rhode Island and a B.S. in pharmacy from Rutgers University.
Charles E. Mather IV
Mr. Mather has been a member of our Board of Directors since March 2018. Since March 2015, Mr. Mather has been Managing Director, Co-Head of Equity Capital Markets at BTIG, LLC. From December 2009 to February 2015 he was the Head of Private and Alternative Capital and Co-Head of Equity Capital Markets at Janney Montgomery Scott, LLC. Between May 2007 and September 2008, Mr. Mather was the head of the Structured Equity Group at Jefferies Group Inc. Prior to that, Mr. Mather held various senior investment banking positions at Cowen and Company, including as Co-Head of the Private Equity Group. Mr. Mather serves on the board of Tonix Pharmaceuticals Holdings Corp. (NASDAQ: TNXP) and Wentz LLC. Mr. Mather also served on the board of the Finance Company of Pennsylvania (OTC: FCPA) until August 2017. Mr. Mather received a B.A. in History from Brown University and an M.B.A. in Finance from The Wharton School at the University of Pennsylvania.
Anthony Y. Sun, M.D.
Dr. Sun has been a member of our Board of Directors since March 2018. He is involved with many private biotechnology companies. Dr. Sun was at Aisling Capital, a private equity firm dedicated to life sciences, from September 2002 until May 2015, during which he held multiple positions most recently as partner. Dr. Sun serves on the board of Versartis, Inc. (NASDAQ: VSAR), Immusoft Corporation, and several other private companies. Dr. Sun holds a B.S. in Electrical Engineering from Cornell University, an M.D. from Temple University School of Medicine, an M.B.A. from The Wharton School at the University of Pennsylvania, trained in internal medicine at the Hospital of the University of Pennsylvania and was Board Certified in Internal Medicine.
Mr. Yoshida has been a member of our Board of Directors since December 2014. Mr. Yoshida has extensive executive and operational experience in the international pharmaceutical industry. Since June 2010, Mr. Yoshida has served in several roles, currently as the Executive Vice President and Chief Operating Officer, at Senju Pharmaceuticals Co., Ltd., a leading, privately owned specialty pharmaceutical research, development, manufacturing and sales company located in Osaka, Japan, with global subsidiaries, branch offices and joint venture relationships throughout the world, including in the United States, Canada, South America, Europe, the Middle East, Asia and Africa. Mr. Yoshida received a Bachelor of Law from Konan University (Kobe, Japan).